Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.
Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.
In an effort to uncover new biomarkers of sensitivity for SCLC, investigators generated PDX models from circulating tumor cells, biopsies, and malignant infusions. The activity of the combination of olaparib and temozolomide was then assessed in a panel of PDX models, responses of which was then compared with molecular profiles to identify candidate biomarkers.
These are early results, but the co-clinical has the potential to refine the clinical application of olaparib and temozolomide in real time, which may optimize clinical trials for SCLC in the future, Drapkin concludes.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More